The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $494,869 in first-year total cost, median $247,435.
Most frequent study sections
- Special Emphasis Panel[ZDA1 JRB-N (O1)]2
Most frequent institutions
- HOWARD UNIVERSITY1
- UNIVERSITY OF TEXAS EL PASO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Development of NLRP3 inhibitors for HIV-associated neuroinflammation in cocaine use.1R21DA059788-01 | BUKRINSKY, MICHAEL ILYAKULKARNI, AMOL ANANT | UNIVERSITY OF TEXAS EL PASO, TX | $263,119 | ZDA1 |
| 2024 | The Role of Endothelial Injury and Myeloid Cell Migration in the Activation of Inflammasomes in HIV infection and Cocaine Exposure1R21DA059784-01 | JEREBTSOVA, MARINA ANEKHAI, SERGEI | HOWARD UNIVERSITY, DC | $231,750 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.